uilding Clinical Capacity for Optimal Asparaginase-Based Treatment in Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma: Approaches in Pediatric, Adult, and Adolescent and Young Adult Patients
Building Clinical Capacity for Optimal Asparaginase-Based Treatment in Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma: Approaches in Pediatric, Adult, and Adolescent and Young Adult Patients
Interactive Practice Guide
Asparaginase, a cornerstone of regimens for acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in pediatric and adult patients, is frequently complicated by a distinct spectrum of toxicities which pose significant clinical management challenges. The management of ALL/LBL in adolescent and young adults (AYA) is particularly complex, and these patients often have reduced survival due to their unique needs, challenges with transitions of care, and divergent management across different providers and settings.
Faculty: Mitchell S. Cairo, MD, Wendy Stock, MD, Emily E. Dworkin, PharmD, BCOP
Release Date:
Expiration Date: September 15, 2027